PubRank

Judy E Garber

Author PubWeight™ 216.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Molecular definition of breast tumor heterogeneity. Cancer Cell 2007 12.67
2 Mutational processes molding the genomes of 21 breast cancers. Cell 2012 11.22
3 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010 9.72
4 Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010 8.93
5 Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011 8.19
6 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002 8.09
7 Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010 5.50
8 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004 5.38
9 BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002 4.38
10 The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006 3.96
11 Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007 3.94
12 RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007 3.63
13 Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008 3.54
14 Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002 3.25
15 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006 3.02
16 NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009 2.78
17 Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005 2.70
18 A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008 2.65
19 Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol 2006 2.53
20 Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006 2.49
21 Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002 2.45
22 Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2010 2.45
23 Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 2013 2.03
24 Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov 2012 2.01
25 Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2011 1.99
26 Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2014 1.79
27 AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev 2007 1.75
28 Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med 2011 1.70
29 Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol 2013 1.67
30 Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 2002 1.60
31 Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw 2014 1.48
32 Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 2008 1.45
33 The feasibility of using natural language processing to extract clinical information from breast pathology reports. J Pathol Inform 2012 1.30
34 American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 2008 1.29
35 Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol 2008 1.29
36 Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 2014 1.28
37 VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008 1.27
38 Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010 1.26
39 F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 2008 1.26
40 Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 2005 1.20
41 Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 2006 1.19
42 The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol 2006 1.18
43 Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 2008 1.18
44 Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 2009 1.17
45 BRCA1/2 genetic testing in the community setting. J Clin Oncol 2002 1.17
46 Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children. Genet Test 2007 1.16
47 The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat 2012 1.15
48 Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med 2009 1.14
49 Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell 2013 1.14
50 Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. Cancer Res 2009 1.14
51 Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS). J Pediatr Psychol 2008 1.12
52 Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw 2015 1.12
53 Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010 1.10
54 Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test 2004 1.09
55 Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 2012 1.09
56 Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007 1.09
57 Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 2006 1.08
58 Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011 1.05
59 Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res 2011 1.05
60 Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007 1.05
61 Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res 2009 1.04
62 Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet 2012 1.04
63 Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 2006 1.03
64 Decisional outcomes of maternal disclosure of BRCA1/2 genetic test results to children. Cancer Epidemiol Biomarkers Prev 2013 1.02
65 Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006 1.01
66 Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 2007 1.01
67 Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov 2011 1.01
68 Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res 2009 1.01
69 RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res 2008 1.01
70 Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011 1.00
71 Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005 0.99
72 Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2006 0.97
73 Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010 0.97
74 A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 2011 0.97
75 Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol 2005 0.95
76 Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol 2012 0.94
77 Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003 0.94
78 The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2005 0.94
79 Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat 2010 0.93
80 Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children. Genet Test Mol Biomarkers 2011 0.93
81 Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J 2009 0.93
82 Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol 2012 0.91
83 Complementary medicine use among women enrolled in a genetic testing program. Cancer Epidemiol Biomarkers Prev 2003 0.91
84 DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res 2010 0.90
85 Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005 0.90
86 Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet 2012 0.90
87 Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations. Cancer Epidemiol Biomarkers Prev 2006 0.89
88 Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy. Psychooncology 2008 0.89
89 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 0.89
90 Breast cancer risk reduction. J Natl Compr Canc Netw 2010 0.88
91 Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol 2004 0.88
92 A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing. Genet Med 2002 0.87
93 Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Gynecol Oncol 2009 0.86
94 Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat 2010 0.85
95 Young adult daughters of BRCA1/2 positive mothers: what do they know about hereditary cancer and how much do they worry? Psychooncology 2013 0.85
96 Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys 2005 0.84
97 Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev 2011 0.84
98 Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. J Clin Oncol 2011 0.84
99 Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer 2014 0.84
100 Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Res Treat 2014 0.83
101 Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together. Patient Educ Couns 2009 0.83
102 Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 2006 0.83
103 Time to think outside the (genetic) box. Cancer Prev Res (Phila) 2011 0.83
104 Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. Cancer Res 2009 0.82
105 Breast cancer screening and diagnosis. J Natl Compr Canc Netw 2006 0.82
106 Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers. Am J Surg Pathol 2012 0.82
107 Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2014 0.81
108 Talking to children about maternal BRCA1/2 genetic test results: a qualitative study of parental perceptions and advice. J Genet Couns 2012 0.81
109 The American Society of Clinical Oncology position on genetic testing: implications for health care providers: workshop no. 4. Cancer 1997 0.81
110 Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer 2014 0.81
111 The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006 0.80
112 Male patients with diagnoses of both breast cancer and prostate cancer. Breast J 2003 0.80
113 Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Mol Cancer Res 2009 0.79
114 Breast cancer screening: a final analysis? CA Cancer J Clin 2003 0.79
115 Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med 2014 0.79
116 One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers. J Natl Cancer Inst 2004 0.78
117 Family cancer history: healthy skepticism required. J Natl Cancer Inst 2011 0.78
118 Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side. J Clin Oncol 2009 0.78
119 Breast cancer risk reduction. J Natl Compr Canc Netw 2007 0.78
120 Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations. J Clin Oncol 2012 0.78
121 Ethical issues in cancer genetics: I 1) whose information is it? J Genet Couns 2006 0.78
122 Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat 2013 0.77
123 Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome. Fam Cancer 2011 0.77
124 Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon? Breast Cancer Res Treat 2005 0.76
125 Women's concerns about the emotional impact of awareness of heritable breast cancer risk and its implications for their children. J Community Genet 2014 0.75
126 Quality or quantity in the management of hereditary ovarian cancer risk: Is it really a trade-off? J Clin Oncol 2005 0.75
127 Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS). Ann Surg Oncol 2015 0.75
128 Breast MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for use. Ann Surg Oncol 2007 0.75
129 Familial cancer database online. Lancet Oncol 2008 0.75